GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz
Emily
E
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000639:trends; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D000077341:Lapatinib; D040541:Marketing / Q000191:economics; D009369:Neoplasms / Q000188:drug therapy* / Q000191:economics*; D011799:Quinazolines / Q000191:economics* / Q000627:therapeutic use*; D000068878:Trastuzumab; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D011799:Quinazolines; D000077341:Lapatinib; D000068878:Trastuzumab